semaglutide gi obstruction lawsuit in michigan Novo Nordisk is suing Eli Lilly over its GLP-1 ads, accusing the rival drugmaker of false advertising for claiming Lilly's Mounjaro and Zepbound outperform Novo's Ozempic and Wegovy. MORE BELOW ⬇️ semaglutide ileus legal team in

weakened immunity

The American Diabetes Association (ADA) guidelines recommend specific GLP-1 agonists with proven cardiovascular benefit (such as liraglutide, injectable semaglutide, and dulaglutide) for patients with type 2 diabetes and established atherosclerotic cardiovascular disease

UW ECHO Dementia November 14, 2025 : GLP-1 Therapy and the Brain Arthi Thirumalai, MD, Associate Professor, UW School of Medicine Recording [YouTube] Slides [PDF] Resources: Cummings JL, Atri A,Feldman HH, et al

A1 : Promotes efficient energy metabolism, helping the body utilize fat for energy, leading to increased calorie burning and potential weight loss

Gen Z was more likely to state cost savings as a reason for starting a GLP-1